Alfonso G. Zulueta
Known title: DirectorCIK: 0001596336
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
CLDI Included in After-Market Movers List. Calidi Biotherapeutics was listed among 12 health care stocks moving in Tuesday's after-market session. The stock is currently trading near its 52-week low of $1.03, reflecting significant volatility. This inclusion highlights recent price action in the biotech sector.
Transaction History
| CTS | ▲ Buy | Grant | 3,500 | $0 | 11/6/2025 | View on chart |
| CTS | ▲ Buy | Grant | 2,400 | $0 | 11/7/2024 | View on chart |
| CLDI | ▲ Buy | Grant | 5,644 | $10K | 12/21/2023 | View on chart |
| CTS | ▲ Buy | Grant | 3,600 | $0 | 11/2/2023 | View on chart |
| CTS | ▲ Buy | Grant | 3,100 | $0 | 11/10/2022 | View on chart |
| CTS | ▲ Buy | Grant | 3,600 | $132K | 11/4/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Analyst Initiates Coverage on CTS with $67 Price Target
Lake Street initiated coverage on CTS Corporation this week, assigning a Buy rating and $67 price target. The analyst pointed to CTS's expanded current sensing distribution capabilities as a key driver, with separate analysis suggesting the stock could be trading approximately 14% below its assessed value based on this push. Q2 comparisons showed CTS performing in line with peers in the electronic components and manufacturing sector. The stock is currently trading near its 52-week range at the $60 support level, having touched its 200-day moving average recently.
Analyst Initiates Coverage on CTS with $67 Price Target. Lake Street initiated coverage on CTS Corporation this week, assigning a Buy rating and $67 price target. The analyst pointed to CTS's expanded current sensing distribution capabilities as a key driver, with separate analysis suggesting the stock could be trading approximately 14% below its assessed value based on this push. Q2 comparisons showed CTS performing in line with peers in the electronic components and manufacturing sector. The stock is currently trading near its 52-week range at the $60 support level, having touched its 200-day moving average recently.